NN & Sanofi Sign Gabitril License Deal
Novo Nordisk has signed a licensing agreement with Sanofi for worldwiderights, except for the Americas and Japan, on its antiepileptic drug Gabitril (tiagabine). The agreement will be effective from January 15, 1998, with Sanofi taking over all marketing and promotional activities from March. Financial details were not disclosed.
Gabitril, which Sanofi claims has potential peak sales of some $150 million, has been approved in more than 15 countries, and launched in Denmark, Germany, Austria, Switzerland, Ireland, Finland and France. It was also recently launched in the USA by partner Abbott Laboratories.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze